相关实验视频
Updated: Jun 26, 2025

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
移植后复发的补充介导血清性尿素综合征 移植后的复发性补充介导血清性尿素综合征
Shota Obata1, Frank Hullekes2, Leonardo V Riella3
1Precision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
补充介导的血溶性尿性综合征 (cHUS) 涉及补充替代途径基因突变. 埃奎利祖马布显著减少了移植中cHUS的复发,改善了结果,尽管仍然存在治疗中止问题.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 遗传性血溶性尿素综合征 (HUS),现在被称为补充介导的HUS (cHUS),由补充替代途径的遗传缺陷引起.
- 在移植患者中,cHUS存在高复发风险,往往导致移植失败.
- 反补充C5抗体eculizumab已经彻底改变了cHUS的治疗方法,大大降低了复发率并提高了移植的存活率.
研究的目的:
- 审查cHUS的病理生理学,分类和遗传基础.
- 探索当前和新兴的管理策略,用于cHUS在原生和移植脏.
- 为了解决关键的问题,关于补充抑制剂的中止和患者选择的治疗中止.
主要方法:
- 关于cHUS,补充途径和eculizumab治疗的综合文献综述研究.
- 分析遗传倾向及其对cHUS病理生理学的影响.
- 用eculizumab治疗的cHUS移植患者临床结果的评估.
主要成果:
- 补充替代途径基因的突变是cHUS发育的核心.
- 治疗eculizumab在预防移植后cHUS复发方面表现出显著的有效性.
- 停止治疗eculizumab和以遗传标记为指导的患者选择的最佳策略需要进一步研究.
结论:
- 通过补充抑制,特别是eculizumab,转化了cHUS的管理,改善了移植结果.
- 了解遗传因素对于个性化的cHUS治疗和管理至关重要.
- 需要进一步的研究来确定治疗停止和长期管理cHUS患者的协议.
更多相关视频
06:29Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
相关概念视频
Cell-mediated Immune Responses
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...